1.
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2010; 20 (6): 423
en Inglés
| IMEMR
| ID: emr-98110
2.
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2008; 18 (3): 176-178
en Inglés
| IMEMR
| ID: emr-100294
RESUMEN
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response
Asunto(s)
Humanos , Masculino , Pirimidinas/efectos adversos , Piperazinas/efectos adversos , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico
3.
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2008; 18 (9): 576-577
en Inglés
| IMEMR
| ID: emr-102969
RESUMEN
The spectrum of plasma cell neoplasm represents indolent conditions like Monoclonal Gammopathy of Undetermined Significance [MGUS] to more aggressive multiple myeloma and plasma cell leukemia. Non-secretory myeloma comprises less than 01% of this spectrum where serum protein electrophoresis and quantitative immunoglobulins remain essentially normal. We are presenting a case report of this rare variant involving the sternum of an adult male